SCHEMBL164718

SCHEMBL164718

N#Cc1c(N)cccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 5/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NR4A2 P43354 1/20 0.46
GAA P10253 2/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 2/20 0.43
KMT2A Q03164 2/20 0.43
ALOX15 P16050 1/20 0.43
CASP1 P29466 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP3A4 P08684 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
ADORA2A P29274 5/20 0.40
ADORA1 P30542 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29555850 1.00 TSHR (0.48) TSHRALDH1A1KDM4EL3MBTL1NR4A2
Dichlobenil SCHEMBL55606 0.83 ALDH1A1 (0.55) TSHRALDH1A1KDM4EL3MBTL1GAA
SCHEMBL1398115 0.83 ALDH1A1 (0.43) TSHRALDH1A1KDM4EL3MBTL1GAA
Dichlobenil SCHEMBL1701380 0.83 ALDH1A1 (0.55) TSHRALDH1A1KDM4EL3MBTL1GAA
Dichlobenil SCHEMBL28232070 0.80 ALDH1A1 (0.53) TSHRALDH1A1KDM4EL3MBTL1GAA
Dichlobenil SCHEMBL10737856 0.80 ALDH1A1 (0.53) TSHRALDH1A1KDM4EL3MBTL1GAA
SCHEMBL28027128 0.79 TSHR (0.50) TSHRALDH1A1KDM4EL3MBTL1NR4A2
Dichlobenil SCHEMBL10741379 0.78 ALDH1A1 (0.52) TSHRALDH1A1KDM4EL3MBTL1GAA
SCHEMBL9129444 0.78 CYP1A2 (0.57) TSHRALDH1A1KDM4EL3MBTL1GAA
SCHEMBL6149211 0.77 TSHR (0.48) TSHRALDH1A1KDM4ENR4A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3813532-B1 PROCESS FOR THE PREPARATION OF QUINMERAC ADAMA AGAN LTD (IL) 2024-02-28 EP claimed
CN-112423589-B Process for preparing chloroquinolinic acid 安道麦阿甘有限公司 2023-03-10 CN claimed
US-11427545-B2 Process for the preparation of Quinmerac ADAMA AGAN LTD. (IL) 2022-08-30 US claimed
CN-111668481-B Preparation method of metal aluminum secondary battery with multi-group organic micromolecules as positive electrode 北京科技大学 2021-12-03 CN claimed
US-20210147362-A1 PROCESS FOR THE PREPARATION OF QUINMERAC ADAMA AGAN LTD. (IL) 2021-05-20 US claimed
EP-3813532-A1 PROCESS FOR THE PREPARATION OF QUINMERAC Adama Agan Ltd. (IL) 2021-05-05 EP claimed
CN-112423589-A Process for preparing chloroquinolinic acid 安道麦阿甘有限公司 2021-02-26 CN claimed
CN-111668481-A Preparation method of metal aluminum secondary battery with multi-group organic micromolecules as positive electrode 北京科技大学 2020-09-15 CN claimed
EP-2671575-A1 Ras inhibitors Universität Regensburg (DE) 2013-12-11 EP claimed
WO-2025224262-A1 COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 WO disclosed
WO-2025224249-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 WO disclosed
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 EP disclosed
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-08-21 US disclosed
US-20250114466-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES BYONDIS B.V. (NL) 2025-04-10 US disclosed
CN-1032440-A The 4-aminopyridine derivatives class PFIZER (US) 1989-04-19 CN disclosed
EP-0311303-A2 4-aminopyridine derivatives PFIZER INC. (US) 1989-04-12 EP disclosed
WO-1989002740-A1 4-AMINOPYRIDINE DERIVATIVES PFIZER INC. (US) 1989-04-06 WO disclosed
EP-0006999-B1 A PROCESS FOR THE PRODUCTION OF 2-CHLOROBENZONITRILE DERIVATIVES NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1981-04-01 EP disclosed
US-4225534-A FROM CHLORINATED 2-NITROBENZONITRILES NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1980-09-30 US disclosed
EP-0006999-A1 A process for the production of 2-chlorobenzonitrile derivatives NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1980-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114466-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES DHFR, FOLR1, MTHFD2 TSHR 1590/4885ALDH1A1 1219/4885KDM4E 2050/4885
US-11427545-B2 Process for the preparation of Quinmerac NQO2, QARS1, P2RY11 TSHR 4630/4885ALDH1A1 3338/4885KDM4E 2701/4885
US-20210147362-A1 PROCESS FOR THE PREPARATION OF QUINMERAC NQO2, QARS1, P2RY11 TSHR 4630/4885ALDH1A1 3338/4885KDM4E 2701/4885
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CDK2, SKP2, CDK1 TSHR 3902/4885ALDH1A1 3818/4885KDM4E 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.